Frontiers in Hematology

Case Report

Accepted on 12 Feb 2025

Triplet combination with Pirtobrutinib/Venetoclax/Rituximab in Accelerated Phase of Chronic Lymphocytic Leukemia

in Blood Cancer

Andrea Serafin
Alessandro Cellini
Francesco Angotzi
Valeria Ruocco
Arianna Bevilacqua
Marco Pizzi
LIVIO TRENTIN
ANDREA VISENTIN

Frontiers in Hematology

doi 10.3389/frhem.2025.1552200

120 views

Review

Accepted on 10 Feb 2025

Abnormalities of the primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, coagulation system, and bone marrow microenvironment

in Blood Cancer

Jahan Abdi
Payman Nasr

Frontiers in Hematology

doi 10.3389/frhem.2025.1435193

Case Report

Accepted on 04 Feb 2025

Acquired von Willebrand Disease associated with Smoldering Multiple Myeloma and Hereditary Hemorrhagic Telangiectasia successfully treated with Daratumumab, Pomalidomide, and Dexamethasone: Hitting three birds with one stone?case report

in Blood Cancer

Lemchukwu Amaeshi
Mansour Gergi
Jacqueline Poston

Frontiers in Hematology

doi 10.3389/frhem.2025.1499500

104 views

Original Research

Accepted on 04 Feb 2025

Time to Initiation of Antiresorptive Agents in Multiple Myeloma to Reduce Skeletal Related Events

in Blood Cancer

Amman Bhasin
Adam Finn Binder
Leland Damron
Amry Majeed
Adam Barsouk
Kelly Hughes
Niketa Raj
Abdullateef O Abdulkareem
Tingting Zhan
Divya Polu

Frontiers in Hematology

doi 10.3389/frhem.2025.1521017

Original Research

Published on 21 Jan 2025

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

in Blood Cancer

Sam Salek
Samantha Nier
Zack Pemberton-Whiteley
Tatyana Ionova
Giuseppe Ianni
Giovanni Tripepi
Nick York
Nicole Schroeter
Kathryn Huntley
Michael Rynne

Frontiers in Hematology

doi 10.3389/frhem.2024.1502166

1,167 views

Case Report

Published on 16 Jan 2025

Case report: VEXAS syndrome: first documented cases in Latin America

in Blood Cancer

Carolina Ottati
Inés Gervaz
Martín Yandian
Matilde Boada
Gabriela Vidal-Senmache
Percy Ortiz-Guerra
Ana I. Catalán
Patricia Kutscher
Diego Lopez
Lilian Diaz

Frontiers in Hematology

doi 10.3389/frhem.2024.1501337

178 views

Case Report

Published on 10 Jan 2025

Case report: A decade-long journey with cyclic thrombocytopenia

in Blood Cancer

Talal Al-Assil
Suhaib Ellythy
Omer A. Idris
Mohammad Omaira

Frontiers in Hematology

doi 10.3389/frhem.2024.1482891

194 views

Mini Review

Published on 24 Dec 2024

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

in Blood Cancer

Joshua W. Bliss
Spencer Krichevsky
Joseph Scandura
Ghaith Abu-Zeinah

Frontiers in Hematology

doi 10.3389/frhem.2024.1504327

433 views

Case Report

Published on 17 Dec 2024

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

in Blood Cancer

Monika A. Satoskar
Matthew R. Lordo
Daniel M. Jones
Nicholas B. Nowacki
Jonathan E. Brammer
John C. Reneau
Timothy J. Voorhees

Frontiers in Hematology

doi 10.3389/frhem.2024.1463487

337 views

Case Report

Published on 12 Dec 2024

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

in Blood Cancer

Selene Grano
Valentina Bonuomo
Diana Carli
Veronica Peri
Loredana Farinasso
Ugo Ramenghi
Daniela Cilloni
Carmen Fava

Frontiers in Hematology

doi 10.3389/frhem.2024.1508463

207 views

Study Protocol

Published on 06 Dec 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

in Blood Cancer

Theo Leitner
Evgenii Shumilov
Christina Schwitlick
Raphael Koch
Franziska Hamm
Marion Högner
Florian Bassermann
Katja Weisel
Hermann Einsele
Martin Kortüm

Frontiers in Hematology

doi 10.3389/frhem.2024.1436845

653 views

Original Research

Published on 05 Dec 2024

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

in Blood Cancer

Manuel Neves
Rita Gerivaz
Graça Esteves
Rui Bergantim
Gisela Ferreira
Henrique Coelho
Celina Afonso
Delfim Duarte
Anabela Neves
Helena Matos Silva

Frontiers in Hematology

doi 10.3389/frhem.2024.1480120

405 views

Original Research

Published on 22 Nov 2024

Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

in Blood Cancer

Somedeb Ball
Najla H. Al Ali
Akriti G. Jain
Luis E. Aguirre
Seongseok Yun
Onyee Chan
Zhuoer Xie
David A. Sallman
Jeffrey Lancet
Eric Padron

Frontiers in Hematology

doi 10.3389/frhem.2024.1492680

269 views

Case Report

Published on 13 Nov 2024

Case report: VEXAS syndrome and literature review

in Blood Cancer

Can Jones
Stanislav Ivanov
Pablo Ferraro
Souhad Younes
Hugo Fernandez

Frontiers in Hematology

doi 10.3389/frhem.2024.1480436

297 views

Mini Review

Accepted on 05 Nov 2024

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults

in Blood Cancer

Linda Resar
Tania Jain

Frontiers in Hematology

doi 10.3389/frhem.2024.1483322

Review

Published on 29 Oct 2024

Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

in Blood Cancer

Binsah George
Kok Hoe Chan
Adan Rios

Frontiers in Hematology

doi 10.3389/frhem.2024.1463410

1,242 views

Navigation group

Articles

Triplet combination with Pirtobrutinib/Venetoclax/Rituximab in Accelerated Phase of Chronic Lymphocytic Leukemia

Abnormalities of the primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, coagulation system, and bone marrow microenvironment

Acquired von Willebrand Disease associated with Smoldering Multiple Myeloma and Hereditary Hemorrhagic Telangiectasia successfully treated with Daratumumab, Pomalidomide, and Dexamethasone: Hitting three birds with one stone?case report

Time to Initiation of Antiresorptive Agents in Multiple Myeloma to Reduce Skeletal Related Events

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

Case report: VEXAS syndrome: first documented cases in Latin America

Case report: A decade-long journey with cyclic thrombocytopenia

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

Case report: VEXAS syndrome and literature review

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults

Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring